Bristol-Myers SquibbBMY.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Bristol-Myers Squibb (BMY.N) trades at a P/E of 13.10x, P/B of 5.50x, P/S of 2.48x, and a dividend yield of 4.22%.
Longitudinal percentile comparison: P/E sits at the 9th percentile over the trailing 10Y window (vs. 23rd percentile over 3Y); P/B sits at the 58th percentile over the trailing 10Y window (vs. 43rd percentile over 3Y); P/S sits at the 24th percentile over the trailing 10Y window (vs. 81st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 19th percentile within its industry and the 31st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.22%, ranking at the 44th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 49.0 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Bristol-Myers Squibb operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: BMY · BMY
Want the full picture on whether Bristol-Myers Squibb (BMY.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 13.10 | ||||||
| P/B (MRQ) | 5.50 | ||||||
| P/S (TTM) | 2.48 | ||||||
| Dividend Yield | 4.22% | ||||||
| Buyback + Div Yield | 4.22% |